Evidence map›Paper›PMID 23590229›Full record

ArticleTropical medicine & international health : TM & IH2013

Initiation of antiretroviral therapy in HIV-infected tuberculosis patients in rural Kenya: an observational study.

Alexander J Stockdale, Joseph Nkuranga, M Estée Török, Brian Faragher, David G Lalloo

Abstract read
In one paragraph

Article in Tropical medicine & international health : TM & IH, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alexander J StockdaleRegional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK. alexstockdale@doctors.org.uk
Joseph Nkuranga
M Estée Török
Brian Faragher
David G Lalloo

Funding

Wellcome Trust 087791Wellcome Trust 100890
6 · The paper itself

Abstract

objectiveTo provide information on the effect of timing of antiretroviral therapy (ART) initiation on outcomes of TB infection in real-life, non-clinical trial, rural settings in sub-Saharan Africa.

methodsWe conducted an observational cohort study of all HIV-infected TB patients presenting to a rural hospital in Kenya between 2005 and 2009. We analysed the association between timing of initiation of ART and mortality, using a Cox regression survival analysis, adjusted for measured confounders.

resultsA total of 404 antiretroviral-naïve HIV/TB coinfected patients were included in the study. Initiation of ART during the first 8 weeks of TB treatment (early group) was not associated with changes in mortality at 1 year compared with initiation of ART after 8 weeks (late group) [Hazard Ratio (HR) = 0.74 (Confidence Interval (CI), 0.33-1.64, P = 0.46]. In patients with baseline CD4 counts ≤50 cells/μl, there was a significant reduction in mortality in the early group compared with the late group (HR = 0.20; 95% CI, 0.042-0.99; P = 0.049). In patients with a CD4 count >50 cells/μl, there was no significant difference between early and late groups (HR 1.79; 95% CI, 0.64-5.03; P = 0.27).

conclusionsWe found that in HIV/TB coinfected patients in rural Kenya, early ART initiation (within 8 weeks) was associated with reduced mortality in those with CD4 counts ≤50 cells/μl. In patients with CD4 counts >50 cells/μl, there was no association seen between timing of ART and mortality.

Indexed as

Antiretroviral Therapy, Highly ActiveAdolescentAdultAnti-HIV AgentsCD4 Lymphocyte CountConfidence IntervalsDrug Administration ScheduleFemaleHIV InfectionsHumansKenyaMaleMiddle AgedProportional Hazards ModelsQualitative ResearchRural PopulationAnti-HIV Agents

Identifiers

PMID23590229
PMCPMC3999513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.